Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Early Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03676725Early Phase 1Completed

Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

Role: lead

NCT04856956Not ApplicableUnknown

Testing Pediatric Rheumatology Diagnostic Decision Support in Clinical Use

Role: lead

NCT04167189Early Phase 1Completed

Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD

Role: lead

NCT03680885Early Phase 1Completed

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

Role: lead

All 4 trials loaded